ALISO VIEJO, Calif., June 16, 2014 (GLOBE NEWSWIRE) -- CNS Response, Inc. (OTCBB:CNSO):

CNS Response will be showcasing PEER, technology to guide psychiatric treatment, at the June 18 AdvaMed Veterans & Medical Technology event on Capitol Hill. This event highlights innovative technologies available today that are addressing the health care needs of our veterans and military personnel.

PEER is a crowd-sourced outcome registry that provides physicians with objective data to guide treatment by using EEG, a well-normed and inexpensive measure of brain function, paired with outcome data.

Over 84 peer reviewed studies of the technology used in PEER demonstrate that objective data can do for Psychiatry what data registries have done to improve outcomes in other medical specialties. Treatment effectiveness is doubled versus trial and error, the current standard of care for depression, PTSD and anxiety. Adherence to treatment by patients and productivity by doctors are also increased. 96% of Depression patients want more information, and think more highly of their practitioner when it is provided.

Advancements in medical technology can improve access to care, while helping to reduce health care costs. Dr. John Bradley, VA Boston Chief of Psychiatry has said, "This could revolutionize prescribing practice in terms of helping people get the right treatment sooner."

CNS Response and Walter Reed National Military Medical Center are currently involved in a 2,000 soldier trial, performed under a public-private partnership.

About CNS Response

CNS Response provides reference data and analytic tools for clinicians and researchers in psychiatry. While treatment for mental disorders has doubled in the last 20 years, it is estimated that 17 million Americans have failed two or more medication therapies for their mental disorders. The company's Psychiatric EEG Evaluation Registry, or PEER Online, is a new registry and reporting platform that allows medical professionals to exchange treatment outcome data for patients referenced to objective neurophysiology data obtained through a standard electroencephalogram (EEG). Based on the company's original physician-developed database, there are now more than 38,000 outcomes for 9,800 unique patients in the PEER registry. The objective of PEER Online is to avoid trial and error pharmacotherapy which is the dominant approach for treatment resistant patients.

To read more about the benefits of this patented technology for patients, physicians and payers, please visit www.cnsresponse.com. Medical professionals interested in learning more can contact CNS Response at PEERinfo@cnsresponse.com.

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995

Except for the historical information contained herein, the matters discussed are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These forward-looking statements involve risks and uncertainties as set forth in the Company's filings with the Securities and Exchange Commission. These risks and uncertainties could cause actual results to differ materially from any forward-looking statements made herein.